US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Targinta’s CEO to BioStock: “Strong interest in ADCs in 2023”

During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This signals a continued strong interest in the field. AbbVie made a multi-billion dollar acquisition of ImmunoGen, Merck entered into a development agreement with Daiichi, and Pfizer acquired Seagen for a record amount. Evy Lundgren-Åkerlund, CEO of ADC developer Targinta, shares her analysis.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/targintas-ceo-strong-interest-in-adcs-in-2023/

BioStock: Xintela highlights the unique properties of XSTEM

Biopharma company Xintela develops stem cell products with therapeutic properties aiming to treat diseases that currently lack effective treatment options. The company´s stem cells stand out from others through a selection step in the production process that provides quality-assured, homogenous and pure stem cell preparations. BioStock talked to Lucienne Vonk, Director Musculoskeletal Diseases at Xintela, about the benefits of the company’s stem cell products.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/xintela-highlights-the-unique-properties-of-xstem/

BioStock: Xintela initiates last dose level in knee osteoarthritis study

Xintela recently announced that they have initiated the third and last dose level in the phase I/IIa study with the stem cell product XSTEM in patients with knee osteoarthritis. The company’s goal is to present safety data from all dose levels and early efficacy results in 2023. BioStock contacted Camilla Wennersten, Director Clinical Development at Xintela, to find out more about the study.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/xintela-initiates-last-dose-level-in-knee-osteoarthritis-study/ This is a press release from BioStock - Connecting

BioStock Studio:Xintela’s chairman about the company’s journey

Gregory Batcheller has been the chairman of biopharma Xintela since 2011. During this time he has seen the company reach several milestones and now has two ongoing clinical phase I/IIa studies with XSTEM. Batcheller visited BioStock’s studio to tell us more about the company’s journey and business development.See the interview at biostock.se: https://www.biostock.se/en/2023/03/xintelas-chairman-about-the-companys-journey/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Targinta positions itself in the ADC field

The Antibody-Drug Conjugates area has grown rapidly in recent years with several research advances, market approvals, and licensing agreements. A clear example is Pfizer's 43 billion USD acquisition of Seagen announced on March 13. Swedish Targinta, with its unique cancer target and First-in-Class antibodies, has developed a strong position in the ADC field.Read the full article at biostock.se: https://www.biostock.se/en/2023/03/targinta-positions-itself-in-the-adc-field/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Xintela’s strategy for 2023

2022 was an eventful and successful year for Xintela. The company entered into clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers and thus has two ongoing clinical phase I/IIa studies with XSTEM. In addition, further development of EQSTEM for the treatment of joint diseases in horses is planned. In parallel with the stem cell projects, a phase 0 study is being prepared in the subsidiary Targinta. Xintela’s CEO Evy Lundgren-Åkerlund tells us more about the plans for 2023 in an interview with BioStock.Read the full article at biostock.se:

BioStock:Targinta takes lead in the ADC field in the Nordics

Targinta has selected the first ADC drug candidate, TARG9, which is armed with a powerful toxin, primarily for the treatment of triple-negative breast cancer and glioblastoma. With this, the company is established as a leading player in the Nordics in the field of so-called antibody-drug conjugates. BioStock dives deep into the potential and benefits of the ADC technology.Read the full article at biostock.se : https://www.biostock.se/en/2022/05/targinta-takes-lead-in-the-adc-field-in-the-nordics/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock: Targinta’s CEO comments on preclinical data in TNBC and the spin-out

The oncology company Targinta recently presented new preclinical data on TARG10 at the AACR Annual Meeting. The results show that the cell surface marker integrin α10β1 is selectively expressed in aggressive forms of triple-negative breast cancer (TNBC) and that TARG10 inhibits metastasis of TNBC. BioStock contacted Targinta’s CEO Per Norlén to find out more about the preclinical results, and why the spin-out from the parent company Xintela is now being postponed.Read the full article at biostock.se: https://www.biostock.se/en/2022/04/targintas-ceo-comments-on-preclinical-data-in-tnbc-

BioStock: Xintela’s CEO sees potential in difficult-to-heal wounds

Difficult-to-heal wounds are a painful and costly problem that Xintela has chosen to address. This year, the company will start a phase I/II study with the stem cell product XSTEM in patients with difficult-to-heal leg ulcers. The market potential and medical needs in this area are extensive, says CEO Evy Lundgren-Åkerlund, whom BioStock has interviewed.Read the full article at biostock.se: https://www.biostock.se/en/2022/04/xintelas-ceo-sees-potential-in-difficult-to-heal-wounds/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Xintela presents the plans for 2022 in its Q4 report

Xintela recently published its fourth quarter report, which describes the company’s plans for 2022. During the year, the stem cell product XSTEM will enter clinical trial for the first time in humans in two different phase I/IIa clinical studies; one in knee osteoarthritis and one in difficult-to-heal leg ulcers, the latter of which will be partly financed by a grant of 4.8 MSEK from Vinnova.Read the full article at biostock.se: https://www.biostock.se/en/2022/03/xintela-presents-the-plans-for-2022-in-its-q4-report/ This is a press release from BioStock - Connecting Innovation &

BioStock: Xintela advances to clinical phase in OA and difficult-to-heal wounds in 2022

There has been no shortage of news in 2021 for Xintela. With positive study results in several indications, as well as a newly recruited CEO to lead the subsidiary Targinta, Xintela is looking ahead to 2022 as they are expected enter clinical phase with two of their development projects. BioStock contacted Xintela’s CEO Evy Lundgren-Åkerlund to find out more about the progress in 2021 and the plans for 2022.Read the full article at biostock.se: https://www.biostock.se/en/2022/01/xintela-advances-to-clinical-phase-in-oa-and-difficult-to-heal-wounds-in-2022/ This is a press release from

BioStock: Xintela approaches the market with EQSTEM

Drug development company Xintela continues to take steps towards the market with the stem cell product EQSTEM. Recently, a preclinical study was completed showing that the product reduces lameness in horses that have osteoarthritis due to joint injury. Based on these results, the company continues to develop EQSTEM towards market approval. BioStock reached out to Professor Casper Lindegaard, who was involved in the horse study with EQSTEM, for a comment.Read the full interview with Professor Casper Lindegaard at biostock.se: https://www.biostock.se/en/2021/11/xintela-approaches-the-

BioStock: Targinta’s CEO on TARG10 and the spin-off

Targinta has selected its first drug candidate TARG10, which shows an inhibitory effect on tumour growth and reduced metastasis in triple-negative breast cancer. In addition, the company is in an intensive phase where it is preparing for a spin-off from the parent company Xintela. BioStock contacted Targinta’s CEO Per Norlén to learn more about TARG10 and the spin-off.Read the interview with Targinta's CEO Per Norlén at biostock.se: https://www.biostock.se/en/2021/10/targintas-ceo-on-targ10-and-the-spin-off/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock Studio: Xintela expands to venous leg ulcers

Xintela has broadened the clinical development of its stem cell product XSTEM to include venous leg ulcers, the most common form of difficult-to-heal wounds in humans. Together with the Burn Centre at Linköping University Hospital, the company has shown that XSTEM provides good wound healing in a preclinical model. The next step for the company will be to apply for a clinical study in patients with venous leg ulcers, a study that Professor Folke Sjöberg from the Burn Centre tells us more about below.Watch the interview with Professor Folke Sjöberg at biostock.se: https://www.biostock.se/

BioStock: Targinta’s new CEO has started

On September 1, Per Norlén took on the role of CEO of Targinta, Xintela's oncology subsidiary, which is being prepared to be spun off from Xintela in 2021. Norlén plans to develop Targinta to become an independent and self-funded cancer company, which he talks more about in an interview with BioStock.Read the full interview with Targinta's CEO Per Norlén at biostock.se: https://www.biostock.se/en/2021/09/targintas-new-ceo-has-started/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Xintela signs agreement with CRO for phase I/II study

Biopharma company Xintela continues to take important steps towards its first clinical trial with the drug candidate XSTEM-OA. This spring, the company was granted permission to produce cell therapy products in its own GMP facility and has now signed an agreement with the Australian CRO GreenLight Clinical to conduct the first clinical trial in humans with the candidate.Read the full interview with Evy Lundgren-Åkerlund at biostock.se:https://www.biostock.se/en/xintela-signs-agreement-with-cro-for-phase-i-ii-study/This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Xintela’s CEO on successful studies and approved GMP facility

May has been an eventful month for Xintela with a steady stream of good news, including positive preclinical results that show that the company’s stem cell product XSTEM repairs damaged cartilage in an animal model and has great potential to become a so-called DMOAD (disease modifying osteoarthritis drug). Shortly after that, Xintela announced that it had chosen difficult-to-heal (chronic) wounds as a new indication, and that XSTEM had already shown excellent wound healing ability in a preclinical wound model. More recently, Xintela also received permission from the Medical Products Agency to

BioStock: New CEO for Xintela's subsidiary Targinta

Xintela recently achieved an important milestone towards the goal of spinning out its subsidiary Targinta when Per Norlén was recruited as CEO and CMO for the company. Norlén has vast experience in early-stage drug development and antibody-based cancer drugs, which will be very useful in Targinta. BioStock reached out to Per Norlén to hear his thoughts on his mission to lead and develop Targinta.Read the full article at biostock.se: https://www.biostock.se/en/new-ceo-for-xintelas-subsidiary-targinta/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock: Xintela’s CEO on recent successes

Recently, promising results from Xintela’s preclinical glioblastoma study were published in the reputable journal Cancers. In addition, the company has obtained an approved patent for the stem cell product XSTEM from the European Patent Office and a tissue establishment license from the Medical Products Agency. BioStock contacted Xintela’s CEO Evy Lundgren-Åkerlund to learn more about the recent positive news.Read the full article at biostock.se:https://www.biostock.se/en/xintelas-ceo-on-recent-successes/ This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Xintela is preparing for progress in 2021

Xintela’s focused and goal-oriented work during 2020 led to the company reaching several milestones. Preparations are now underway for a clinical phase I/II study with XSTEM-OA, Xintela’s stem cell treatment for osteoarthritis. The study will be initiated when a manufacturing license is received from the Medical Products Agency enabling the company to produce stem cells in its own GMP facility. BioStock contacted CEO Evy Lundgren-Åkerlund regarding Xintela’s achievements during the past year and the plans for 2021.Read the full article at biostock.se: https://www.biostock.se/en/xintela-

BioStock: Xintela's CEO comments on the positive patent notice

Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. At the end of October, Xintela announced that the European Patent Office (EPO) has issued an ”Intention to grant” for the patent application covering the company’s stem cell product XSTEM. Once the patent is approved, the stem cell product will be protected on the European market for at least another 18 years. BioStock has contacted Evy Lundgren-Åkerlund, CEO of Xintela, to find out more about XSTEM and the patent.Read the full article at biostock.se:

BioStock: Status report Xintela - Integrins marking the future

Xintela was founded in 2009 by Evy Lundgren-Åkerlund based on her research and discoveries on the properties of the marker protein integrin α10β1. Since then, the company has developed new treatments in both cell therapy and oncology with their well-developed technology platform and broad patent portfolio as a basis. BioStock has now published a status report on Xintela.Read the full Xintela status report at biostock.se: https://www.biostock.se/en/status-report-xintela-integrins-marking-the-future/ This is a pressrelease from BioStock Connecting - Innovation & Capital. https://www.

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe